News

The FDA has granted accelerated approval of Wegovy® (semaglutide) for adults with moderate to advanced metabolic ...
A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...
A WOMAN has shared her three go-to recipe which help her stay slim without resorting to Ozempic. Gina Drewalowski, who is on ...
The FDA has approved semaglutide for treating MASH, a significant advancement in liver disease management. Semaglutide, ...
Viking Therapeutics' stock recently tanked after reporting clinical trial results for an oral anti-obesity candidate. The ...
MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.
The European Commission (EC) has granted conditional marketing authorization for Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic metabolic ...
Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...
The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...
The condition starts off as non-alcoholic, or as it is now known metabolic-associated, fatty liver disease. This fat build-up, over time, leads to inflammation and scarring of the liver, reducing the ...
Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.